Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ: ILMN) will release its third-quarter 2026 financial results after the market closes on October 29, 2026.
CEO Jacob Thaysen and CFO Ankur Dhingra will discuss financial and operating results on a conference call that day at 1:30 pm Pacific Time (4:30 pm Eastern Time). A live webcast will be accessible through the Investor Info section of Illumina's website. A replay will be available on the website for at least 30 days after the event.
Illumina (ILMN) introduced SpliceAI2, a genomic AI model designed to help researchers identify disease-relevant genetic variants that affect RNA splicing. Splicing assembles RNA transcripts before protein production; changes can disrupt gene and protein function.
A newly released preprint evaluated the model against the original SpliceAI and alternatives. In matched DNA and disease data from Genomics England cohorts, SpliceAI2 identified 17% more disease-relevant splice variants than other models. Analysis of matched whole-genome and RNA sequencing data from the NIH's Genotype-Tissue Expression Portal showed 34% improved quantification of splice-site usage versus the next best model.
SpliceAI2 was trained on a dataset 100 times larger than the original model's. Illumina says its suite of SpliceAI2, PromoterAI and PrimateAI-3D enables identification of up to twice as many variants with predicted biological impact.
S&P Dow Jones Indices will rebalance the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 before the market opens on September 21, 2026, to keep each index aligned with its target market-cap range.
Dell Technologies, Palo Alto Networks, Arista Networks, and Sandisk will join the S&P 100, while NIKE, Honeywell Aerospace, Simon Property Group, and Colgate-Palmolive exit. Bloom Energy, Everpure, and Illumina will enter the S&P 500, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource, which move to the S&P SmallCap 600. Multiple constituents, including HubSpot, AGNC Investment, Corcept Therapeutics, Brinker International, Herc Holdings, Delek US Holdings, AXT, Arcutis Biotherapeutics, AtriCure, Capri Holdings, Boston Beer, and others shift among the S&P MidCap 400 and S&P SmallCap 600.
Illumina (Nasdaq: ILMN) reported Q2 2026 revenue of $1.16 billion, up 9.5% year over year, with organic revenue growth of 6.5% and rest‑of‑world (excluding Greater China) organic growth of 8.1%. GAAP operating margin was 21.1% and non‑GAAP operating margin 22.5%. GAAP diluted EPS was $1.35, while non‑GAAP diluted EPS was $1.31, up from $1.19 a year earlier.
Operating cash flow was $201 million versus $234 million in Q2 2025, and free cash flow was $162 million versus $204 million. Illumina ended the quarter with $1.17 billion in cash, cash equivalents and short‑term investments. Based on first‑half performance, Illumina raised its 2026 revenue guidance to $4.60–$4.64 billion and increased non‑GAAP EPS guidance to $5.30–$5.40, while keeping non‑GAAP operating margin guidance at 23.4%–23.6%. The company also now expects rest‑of‑world organic revenue growth above 5%, compared to prior guidance of 2%–4%.
Illumina (NASDAQ: ILMN) announced an expansion of its Billion Cell Atlas alliance, adding three new member companies, including AI-native drug developer Formation Bio. Alliance members will use Illumina's large-scale genome-wide perturbation dataset as infrastructure for AI-driven drug discovery, design, and development.
Launched in January 2026 with AstraZeneca, Merck, and Eli Lilly, the Atlas has sequenced over 350 million cells, generating about six petabytes of genomic data across hundreds of healthy and disease-relevant cell types. According to Illumina, partners can use this resource to discover and validate novel targets, study mechanisms of action, refine indication selection, and better match patient subgroups and trial designs, aiming to increase the likelihood that new medicines reach approval.
Illumina (NASDAQ: ILMN) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host an earnings conference call at 1:30 pm PT (4:30 pm ET), with live webcast and 30-day replay available via the company’s investor website.
Illumina (NASDAQ:ILMN) appointed Mike Sullivan as Chief Commercial Officer effective July 20, 2026, and Julie Coletti as Chief Legal Officer effective August 3, 2026. Both join the Executive Leadership Team as the company advances its strategy in genomics, multiomics, and human health.
Sullivan will lead the global commercial organization, bringing over 30 years of commercial leadership across diagnostics, precision medicine, healthcare, and life sciences. Coletti will oversee global legal, regulatory, and government affairs and serve as corporate secretary, drawing on extensive legal and governance experience in life sciences and medical technology.
Illumina (NASDAQ: ILMN) appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. He is Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories.
He brings experience in drug discovery, clinical development, translational medicine, and precision medicine.
IQM Quantum Computers appointed Craig Ciesla, former 10x Genomics (Nasdaq: TXG) VP of Engineering, as Chief Technology Officer and Inés de Vega as Chief Scientist.
The company is preparing for a planned Nasdaq listing via merger with Real Asset Acquisition Corp (Nasdaq: RAAQ), supported by an upsized $146 million PIPE. IQM operates a vertically integrated quantum computing business and has sold 23 quantum computers to date.
Illumina (NASDAQ:ILMN) launched the StrataMap Spatial Solution, an end-to-end, sequencing-based spatial whole-transcriptome platform for single-cell resolution research across large tissue areas.
The system offers up to 2x more unique genes per sample than probe-based panels, supports >2000 samples annually, integrates with NovaSeq/NextSeq, and includes DRAGEN and Illumina Connected Multiomics software for scalable spatial and multiomic analysis. An FFPE-focused version is targeted for initial customer enablement in 2027.